International reference pricing (IRP), also known as external reference pricing (ERP), is one element commonly used when setting the price of medicines in different markets. Some countries will also use IRP to help determine the eligibility of certain products for […]
International Reference Pricing (IRP) 2024: A year in review Read More »
Drug manufacturers faced a variety of hurdles in 2024. Healthcare system reforms, preparation for the EU joint clinical assessments (JCAs) that went live at the end of January 2025, and drug shortages, alongside governments’ focus on cost containment, are only
Key pharma launch trends in 2024 Read More »
Since 2023, the pharmaceutical industry operating in Europe has faced an unprecedented challenge related to drug shortages. Previously, shortages were dictated by production capacity and changing market conditions. However, the largely inflationary-driven negative impact on pharmaceutical developers seen in 2023
Exploring drug shortages in european markets: the causes, analysis, and response Read More »
PD-1 inhibitors have become a paramount achievement in the oncology space and have revolutionised cancer treatment over the last decade. Their success is attributed to two of the first PD-1 inhibitors to be approved, Keytruda (pembrolizumab) and Opdivo (nivolumab). Ten
Keytruda and Opdivo: a decade review Read More »
